MarketCap
Facebook
X
TelegramQuartalsbericht 2022-Q2
hinzugefügt 08.08.2022
ChemoCentryx Anteile 2011-2026 | CCXI
Anteile Jährlich ChemoCentryx
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 69.9 K | 65.7 M | 56.9 M | 49.8 M | 48.4 M | 46.4 M | 43.9 M | 43.3 M | 40.9 M | 35.4 M | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 65.7 M | 69.9 K | 43.1 M |
Anteile Vierteljährlich ChemoCentryx
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 71.2 K | 70.8 K | 70.4 M | 69.9 M | 69.8 K | 69.6 K | 69.5 M | 68.9 M | 63.3 M | 61.3 M | 60.2 M | 58.2 M | 58.1 M | 52.4 K | 50.7 M | 50.3 K | 49.5 K | 48.9 K | 48.8 M | 48.6 M | 48.2 M | 48.1 M | 48.1 M | 47.8 K | 45.8 K | 44.3 K | 44.2 M | 44.1 K | 43.8 K | 43.5 K | 43.4 M | 43.3 M | 43.3 M | 43.1 M | 42.9 M | 42.8 M | 41.3 M | 36.6 M | 36.4 M | 36.2 M | 36.2 M | 32.9 M | 4.39 M | 4.2 M | 4.15 M | 4.39 M |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 70.4 M | 43.5 K | 30.7 M |
Anteile anderer Aktien in der Pharmaeinzelhändler
| Name | Anteile | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
 |
Applied Genetic Technologies Corporation
AGTC
|
45 M | - | - | $ 26.5 M |  USA |
 |
MorphoSys AG
MOR
|
33.4 M | - | 2.43 % | $ 254 M |  Germany |
 |
Allakos
ALLK
|
86.8 M | - | - | $ 28.6 M | USA |
 |
Advaxis
ADXS
|
6.02 M | - | -9.65 % | $ 45.9 M | USA |
 |
Akouos
AKUS
|
34.4 M | - | 0.23 % | $ 488 M | USA |
 |
AlloVir
ALVR
|
15.3 M | - | 4.14 % | $ 49.1 M | USA |
 |
I-Mab
IMAB
|
220 M | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
78.2 M | - | - | $ 1.01 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
810 K | - | -11.43 % | $ 502 K | USA |
 |
Midatech Pharma plc
MTP
|
80.5 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
219 M | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
7.35 M | $ 0.89 | 1.48 % | $ 6.54 M | China |
 |
Biophytis SA
BPTS
|
118 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
44.7 B | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
166 M | $ 22.2 | -2.07 % | $ 3.68 B | USA |
 |
Evogene Ltd.
EVGN
|
40.4 M | $ 0.75 | -4.66 % | $ 27.9 M |  Israel |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
4.58 M | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Molecular Transport
AMTI
|
38.8 M | - | - | $ 10.1 M | USA |
 |
Galapagos NV
GLPG
|
65.5 M | $ 27.87 | -1.94 % | $ 2.69 B |  Belgium |
 |
AIkido Pharma
AIKI
|
14.3 M | - | 1.93 % | $ 17.4 M | USA |
 |
Applied Therapeutics
APLT
|
84.2 M | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
67.7 M | - | -39.0 % | $ 4.57 M | USA |
 |
ImmuCell Corporation
ICCC
|
9.03 M | $ 8.41 | 0.72 % | $ 75.9 M | USA |
 |
Innoviva
INVA
|
67.4 M | $ 23.04 | -2.74 % | $ 1.55 B | USA |
 |
Avenue Therapeutics
ATXI
|
3.13 M | - | -52.27 % | $ 4.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
75 M | - | - | - |  Russia |
 |
Innate Pharma S.A.
IPHA
|
79.5 M | $ 1.49 | 6.43 % | $ 235 M | France |
 |
Inventiva S.A.
IVA
|
39.2 M | $ 4.93 | -1.5 % | $ 138 M | France |
 |
Aeterna Zentaris
AEZS
|
115 M | - | 5.93 % | $ 314 M |  Canada |
 |
Ayala Pharmaceuticals
AYLA
|
15.4 M | - | - | $ 7.46 M | Israel |
 |
AgeX Therapeutics
AGE
|
10.2 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
36.4 M | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
18.8 M | - | 17.91 % | $ 11.1 M | USA |
 |
Atreca
BCEL
|
38.6 M | - | -11.76 % | $ 5.79 M | USA |
 |
BioNTech SE
BNTX
|
244 M | $ 100.87 | -1.17 % | $ 27.2 B | Germany |
 |
Brainstorm Cell Therapeutics
BCLI
|
9.27 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
99.3 M | - | -4.8 % | $ 255 M | USA |
 |
Kamada Ltd.
KMDA
|
44.8 M | $ 8.17 | 0.25 % | $ 260 M | Israel |
 |
Aquestive Therapeutics
AQST
|
107 M | $ 4.05 | -0.98 % | $ 433 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
127 M | $ 22.46 | -3.56 % | $ 2.86 B | USA |
 |
Fennec Pharmaceuticals
FENC
|
28.6 M | $ 6.33 | -5.6 % | $ 181 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
266 M | $ 1.41 | -5.07 % | $ 375 M | Britain |
 |
Aptose Biosciences
APTO
|
2.45 M | - | -45.71 % | $ 1.2 M | Canada |
 |
AstraZeneca PLC
AZN
|
1.42 B | - | - | $ 96.9 B | Britain |
 |
AVROBIO
AVRO
|
44.3 M | - | 1083.1 % | $ 745 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
1.65 M | $ 2.98 | 2.76 % | $ 4.91 M | Israel |
 |
Madrigal Pharmaceuticals
MDGL
|
22.4 M | $ 516.16 | -0.1 % | $ 11.6 B | USA |
 |
BeiGene, Ltd.
BGNE
|
1.42 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Akero Therapeutics
AKRO
|
67.1 M | - | - | $ 3.67 B | USA |
 |
CureVac N.V.
CVAC
|
186 M | - | - | $ 867 M | Germany |